City of Providence

City of Providence — Profile

Company overview. The entity in the case data is the City of Providence, the municipal government of Providence, Rhode Island — not a corporation. It was founded in 1636 by Roger Williams and incorporated as a city in 1832. It is headquartered at Providence City Hall, 25 Dorrance Street, Providence, RI. It is a public-sector entity with no ticker and no corporate parent; it operates under a mayor–council form of government (15-member City Council). The 2020 U.S. Census recorded a population of 190,934, making it Rhode Island's capital and most populous city and the third-largest in New England.

Products / services / operations. Providence is an operating municipal government, not a manufacturer or vendor. It delivers public services including police and fire protection, public works, parks, and the Providence Public School District; it also operates Providence Water, the municipal drinking-water utility. Its economy is anchored by education, healthcare, government, and finance, with Brown University, Rhode Island Hospital, and Lifespan among the largest local employers. For purposes of the litigation below, the city also acts as a self-insured health and welfare benefit plan, reimbursing prescription-drug costs for active and retired public employees and dependents. Because this is a city, "patent portfolio" and NPE-framing concepts do not apply; it holds no asserted patent portfolio.

Patent-litigation posture. The structured data show 2 plaintiff appearances, 0 as defendant. This is not patent-assertion activity: the two tracked entries are the same dispute — City of Providence v. Celgene Corp., filed March 3, 2015 in the U.S. District Court for the District of New Jersey (No. 2:15-cv-01605), later consolidated into In re Thalomid and Revlimid Antitrust Litigation (No. 2:14-cv-06997). The city sues as an end-payor indirect purchaser, not a patentee. Venue is New Jersey, Celgene's home district — not a plaintiff-friendly patent venue like the Eastern District of Texas.

Notable cases / context. The complaint alleged Celgene monopolized markets for Thalomid (thalidomide) and Revlimid (lenalidomide) by blocking generic manufacturers' access to drug samples for FDA-required bioequivalence testing, misusing REMS programs, filing allegedly sham litigation and Citizen Petitions, and obtaining use patents; the city asserted Sherman Act § 2 injunctive claims plus state antitrust, consumer-protection, and unjust-enrichment claims. It was consolidated with a parallel health-fund suit (International Union of Bricklayers). The case data do not indicate any patent claim by the city.